BR112022025901A2 - Composições e métodos para tratar transtorno obsessivo-compulsivo - Google Patents

Composições e métodos para tratar transtorno obsessivo-compulsivo

Info

Publication number
BR112022025901A2
BR112022025901A2 BR112022025901A BR112022025901A BR112022025901A2 BR 112022025901 A2 BR112022025901 A2 BR 112022025901A2 BR 112022025901 A BR112022025901 A BR 112022025901A BR 112022025901 A BR112022025901 A BR 112022025901A BR 112022025901 A2 BR112022025901 A2 BR 112022025901A2
Authority
BR
Brazil
Prior art keywords
compulsive disorder
compositions
methods
obsessive
treat obsessive
Prior art date
Application number
BR112022025901A
Other languages
English (en)
Inventor
Coric Vladimir
Berman Robert
Aguiar Loren
Original Assignee
Biohaven Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Therapeutics Ltd filed Critical Biohaven Therapeutics Ltd
Publication of BR112022025901A2 publication Critical patent/BR112022025901A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSIÇÕES E MÉTODOS PARA TRATAR TRANSTORNO OBSESSIVO-COMPULSIVO. A presente invenção refere-se a um método para tratar transtorno obsessivo-compulsivo em um paciente em necessidade do mesmo, administrando-se ao paciente uma forma de dosagem incluindo uma quantidade eficaz de troriluzol.
BR112022025901A 2020-06-24 2021-06-24 Composições e métodos para tratar transtorno obsessivo-compulsivo BR112022025901A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063043681P 2020-06-24 2020-06-24
PCT/US2021/038789 WO2021262914A1 (en) 2020-06-24 2021-06-24 Compositions and methods for treating obsessive-compulsive disorder

Publications (1)

Publication Number Publication Date
BR112022025901A2 true BR112022025901A2 (pt) 2023-01-10

Family

ID=79281806

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022025901A BR112022025901A2 (pt) 2020-06-24 2021-06-24 Composições e métodos para tratar transtorno obsessivo-compulsivo

Country Status (11)

Country Link
US (1) US20230181541A1 (pt)
EP (1) EP4171554A4 (pt)
JP (1) JP2023531919A (pt)
KR (1) KR20230027189A (pt)
CN (1) CN115968312A (pt)
AU (1) AU2021297249A1 (pt)
BR (1) BR112022025901A2 (pt)
CA (1) CA3187323A1 (pt)
IL (1) IL299301A (pt)
MX (1) MX2022016174A (pt)
WO (1) WO2021262914A1 (pt)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3753561A1 (en) * 2005-04-05 2020-12-23 Yale University Glutamate modulating agents in the treatment of mental disorders
SI3265448T1 (sl) * 2015-03-03 2022-04-29 Biohaven Therapeutics Ltd. Predzdravila riluzola in njihova uporaba
KR20240068766A (ko) * 2015-05-22 2024-05-17 비스타젠 쎄라퓨틱스, 인크. L-４-클로로키누레닌의 치료적 용도
RU2020130837A (ru) * 2018-02-21 2022-03-21 ЭйАй ТЕРАПЬЮТИКС, ИНК. Комбинационная терапия апилимодом и глутаматергическими агентами
BR112020023231A2 (pt) * 2018-05-27 2021-02-23 Biohaven Pharmaceutical Holding Company Ltd. uso de comprimidos desintegrantes orais de riluzol para tratamento de doenças
SG11202100385YA (en) * 2018-07-22 2021-02-25 Biohaven Therapeutics Ltd Use of riluzole prodrugs to treat alzheimer's disease
SG11202100880VA (en) * 2018-08-16 2021-02-25 Biohaven Therapeutics Ltd Use of riluzole oral disintigrating tablets for treating diseases

Also Published As

Publication number Publication date
CA3187323A1 (en) 2021-12-30
JP2023531919A (ja) 2023-07-26
WO2021262914A1 (en) 2021-12-30
US20230181541A1 (en) 2023-06-15
IL299301A (en) 2023-02-01
EP4171554A4 (en) 2024-07-31
KR20230027189A (ko) 2023-02-27
AU2021297249A1 (en) 2023-02-23
CN115968312A (zh) 2023-04-14
EP4171554A1 (en) 2023-05-03
MX2022016174A (es) 2023-01-24

Similar Documents

Publication Publication Date Title
BR112017026739A2 (pt) compostos para uso no tratamento de distúrbios neuromusculares
MX2018003331A (es) Administracion de potenciadores de regulador de la conductancia transmembrana de fibrosis quistica (cftr) deuterados.
MX2022000027A (es) Extracto de ca?amo para tratamiento del dolor, cancer y epilepsia en animales.
BR112014010803A2 (pt) método de tratamento
MY162903A (en) Methods of treatment of pancreatic cancer
BR112015023725A2 (pt) composição de dosagem de filme autossuportante, composição de dosagem de filme, método de tratamento, e, processo de formação de composição de dosagem de filme
EA201500996A1 (ru) Терапевтические применения эмпаглифлозина
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
MX365366B (es) Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné.
TN2019000019A1 (en) Treatment and prevention of sleep disorders
MX2021006985A (es) Metodos para el tratamiento de la depresión.
BR112021019262A2 (pt) Uso de ciclo-his-pro (chp) para prevenir, atenuar ou tratar fibrose
BR112014030279A2 (pt) métodos para tratamento de neutropenia usando agonistas retinóide
EA202193111A1 (ru) Композиции и способы для лечения рака
BR112018014467A2 (pt) tecnologia de sinergismo fármaco-anticorpo para o tratamento de doenças
CR20210514A (es) USO DE REBOXETINA PARA EL TRATAMIENTO DE NARCOLEPSIA (Divisional 2021-0183)
MX2020001164A (es) Composicion para su uso en la prevencion y/o el tratamiento de la mucositis orogastrointestinal inducida por un tratamiento oncologico.
BR112019008241A2 (pt) tratamento do prurigo nodular
MX2017010654A (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres.
ZA202002107B (en) Use of specific sirna against protein s for the treatment of hemophilia
BR112022023928A2 (pt) Uso de canabidiol para o tratamento do transtorno do espectro autista
BR112018069174A2 (pt) tratamento de prurido urêmico
BR112022025901A2 (pt) Composições e métodos para tratar transtorno obsessivo-compulsivo
EA202190226A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ
BR112018005602A2 (pt) composição para tratar dor